phenyl acetate has been researched along with Parkinson Disease in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Larsson, H; Liu, B; Ludvigsson, JF; Lundholm, C; Pedersen, NL; Sjölander, A; Svenningsson, P; Wallin, J; Williams, DM; Wirdefeldt, K | 1 |
| Bucciantini, M; Cesaro, S; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M | 1 |
| Brunetti, G; Calabrese, V; Di Rosa, G; Leri, M; Saul, N; Schmitz-Linneweber, C; Scuto, M; Stefani, M | 1 |
| Huang, T; Ji, L; Shi, H; Xu, Y | 1 |
| Svenningsson, P; Wallin, J | 1 |
| McGilvray, A | 1 |
| Jang, H; Kim, S; Kim, SR; Lee, JM; Oh, YS; Park, SM | 1 |
| Anaya-Martínez, V; Avila-Costa, MR; Colín-Barenque, L; Díaz-Bech, P; Gutierrez-Valdez, AL; Ordoñez-Librado, JL | 1 |
| Araki, H; Inuzuka, T; Kato, T; Moriwaki, H; Murase, M; Nagaki, M; Nishida, H; Tanaka, Y | 1 |
| Anaya-Martinez, V; Avila-Costa, MR; Corona, DR; Gutierrez-Valdez, AL; Martinez-Fong, D; Montiel-Flores, E; Ordoñez-Librado, JL | 1 |
| Araki, H; Hayashi, Y; Hozumi, I; Inuzuka, T; Kato, T; Kimura, A; Koumura, A; Moriwaki, H; Murase, M; Nagaki, M; Nishida, H; Sakurai, T; Tanaka, Y; Yamada, M | 1 |
| Aoyagi, K; Arai, E; Arai, M; Higuchi, Y; Imazeki, F; Katsuno, T; Kuwabara, S; Maruoka, D; Matsumura, T; Nagano, O; Nakagawa, T; Saeki, N; Shiina, A; Uchiyama, T; Yamamoto, T; Yamanaka, Y; Yokosuka, O | 1 |
| Bertoni, JM; Faulkner, MA; Lenz, TL | 1 |
| Sethi, KD | 1 |
| CHESROW, EJ; KAPLITZ, SE; LEVINE, JM; MUSCI, JP; SABATINI, R | 1 |
| GERSTENBRAND, F; HOFF, H; PROSENZ, P | 1 |
| Chen, JJ; Swope, DM | 1 |
| Fukuhara, Y; Ishitani, R; Katsube, N; Kuwae, T; Mizuno, Y; Mochizuki, H; Nakano, T; Nakashima, K; Ohama, E; Sunaga, K; Tajima, H; Takeshima, T; Tanaka, M; Tsuchiya, K | 1 |
| Burghaus, L; Heiss, WD; Herholz, K; Hilker, R; Jacobs, AH; Kalbe, E; Klein, JC; Thomas, AV; Weisenbach, S | 1 |
| Banasch, M; Goetze, O; Mueller, T; Nikodem, AB; Przuntek, H; Schmidt, WE; Wiezcorek, J; Woitalla, D | 1 |
| Iwashita, A; Kita, Y; Matsuoka, N; Mihara, K; Moriguchi, A; Muramatsu, Y; Muramoto, M; Yamazaki, S; Yamazaki, T | 1 |
| Barrientos, N; Chaná, P; de Marinis, A | 1 |
| Koller, W; Marjama-Lyons, J | 1 |
| Muenter, MD; Sharpless, NS; Tyce, GM | 1 |
| Bond, PA | 1 |
5 review(s) available for phenyl acetate and Parkinson Disease
| Article | Year |
|---|---|
Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.
Topics: Acetates; Anti-Inflammatory Agents; Astrocytes; Cyclopropanes; Humans; Inflammation; Leukotriene Antagonists; Lewy Bodies; Microglia; Parkinson Disease; Quinolines; Receptors, Leukotriene; Sulfides | 2021 |
Gabapentin for the treatment of tremor.
Topics: Acetates; Adult; Aged; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Middle Aged; Parkinson Disease; Treatment Outcome; Tremor | 2003 |
Tremor.
Topics: Acetates; Amines; Anticonvulsants; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Electromyography; Essential Tremor; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Levodopa; Motor Cortex; Muscle, Skeletal; Parkinson Disease; Posture; Primidone; Randomized Controlled Trials as Topic; Severity of Illness Index; Somatosensory Cortex; Topiramate; Tremor | 2003 |
Essential tremor: diagnosis and treatment.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Essential Tremor; Gabapentin; gamma-Aminobutyric Acid; Humans; Parkinson Disease; Primidone; Propranolol | 2003 |
Tremor-predominant Parkinson's disease. Approaches to treatment.
Topics: Acetates; Amantadine; Amines; Antiparkinson Agents; Botulinum Toxins; Cholinergic Antagonists; Clonazepam; Clozapine; Cyclohexanecarboxylic Acids; Dopamine Agonists; Electric Stimulation Therapy; Gabapentin; Gamma Rays; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Neurosurgical Procedures; Parkinson Disease; Propranolol; Radiosurgery; Thalamus; Tremor | 2000 |
3 trial(s) available for phenyl acetate and Parkinson Disease
| Article | Year |
|---|---|
Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.
Topics: Acetates; Acetylcholine; Acetylcholinesterase; Aged; Atrophy; Binding, Competitive; Brain; Brain Mapping; Dihydroxyphenylalanine; Dopamine; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Neuropsychological Tests; Parkinson Disease; Piperidines; Positron-Emission Tomography; Synaptic Transmission | 2005 |
Predictors of gastric emptying in Parkinson's disease.
Topics: Acetates; Aged; Breath Tests; Caprylates; Carbon Isotopes; Cross-Sectional Studies; Female; Food; Gastric Emptying; Gastrointestinal Diseases; Humans; Male; Middle Aged; Parkinson Disease; Postprandial Period; Prospective Studies; Radionuclide Imaging; Regression Analysis | 2006 |
Gabapentin and motor fluctuations in Parkinson's disease.
Topics: Acetates; Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Treatment Outcome | 1997 |
17 other study(ies) available for phenyl acetate and Parkinson Disease
| Article | Year |
|---|---|
β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk.
Topics: Acetates; Cyclopropanes; Humans; Parkinson Disease; Quinolines | 2023 |
Insight into the molecular mechanism underlying the inhibition of α-synuclein aggregation by hydroxytyrosol.
Topics: Acetates; alpha-Synuclein; Antioxidants; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Cyclopentane Monoterpenes; Humans; Levodopa; Molecular Structure; Parkinson Disease; Phenylethyl Alcohol; Protein Aggregation, Pathological; Protein Binding; Protein Conformation; Proteolysis; Pyrans | 2020 |
Healthspan Maintenance and Prevention of Parkinson's-like Phenotypes with Hydroxytyrosol and Oleuropein Aglycone in
Topics: Acetates; alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Cyclopentane Monoterpenes; Disease Models, Animal; Dopaminergic Neurons; Parkinson Disease; Phenylethyl Alcohol; Polyphenols; Pyrans; Treatment Outcome | 2020 |
The gut microbiota metabolite propionate ameliorates intestinal epithelial barrier dysfunction-mediated Parkinson's disease via the AKT signaling pathway.
Topics: Acetates; Aged; Animals; Behavior, Animal; Benzopyrans; Butyrates; Case-Control Studies; Disease Models, Animal; Fatty Acids, Volatile; Feces; Female; Gastrointestinal Microbiome; Humans; Intestinal Mucosa; Male; Mice; Middle Aged; Motor Activity; Occludin; Parkinson Disease; Parkinsonian Disorders; Permeability; Propionates; Proto-Oncogene Proteins c-akt; Signal Transduction; Zonula Occludens-1 Protein | 2021 |
Ageing: Restoration project.
Topics: Acetates; Aging; Alzheimer Disease; Animals; Anti-Asthmatic Agents; Cognition Disorders; Cyclopropanes; Estrogens; Female; Hippocampus; Humans; Inflammation Mediators; Leukotrienes; Macaca mulatta; Male; Mice; Neuronal Plasticity; Parkinson Disease; Plasma; Prefrontal Cortex; Quinolines; Rats; Rejuvenation; Sulfides; Synapses | 2016 |
Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Acetates; Adrenergic Agents; Animals; Calcium-Binding Proteins; Cyclopropanes; Cytokines; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Microglia; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Quinolines; Rotarod Performance Test; Substantia Nigra; Sulfides; Tyrosine 3-Monooxygenase | 2017 |
Inhalation of divalent and trivalent manganese mixture induces a Parkinson's disease model: immunocytochemical and behavioral evidences.
Topics: Acetates; Animals; Behavior, Animal; Chlorides; Disease Models, Animal; Dose-Response Relationship, Drug; Feeding Behavior; Inhalation Exposure; Male; Manganese Compounds; Mice; Motor Activity; Organometallic Compounds; Parkinson Disease; Psychomotor Performance; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Carbon Isotopes; Dopamine Agents; Dyskinesias; Female; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2009 |
L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model.
Topics: Acetates; Administration, Inhalation; Animals; Antiparkinson Agents; Chlorides; Corpus Striatum; Disease Models, Animal; Dopamine; Levodopa; Male; Manganese Compounds; Mice; Motor Activity; Organometallic Compounds; Parkinson Disease | 2010 |
Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Breath Tests; Carbon Isotopes; Female; Gastric Emptying; Humans; Male; Middle Aged; Parkinson Disease; Time Factors | 2011 |
Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease.
Topics: Acetates; Aged; Antiparkinson Agents; Breath Tests; Carbon Isotopes; Deep Brain Stimulation; Female; Gastric Emptying; Ghrelin; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics as Topic; Statistics, Nonparametric; Subthalamic Nucleus | 2012 |
Use of ethyltryptamine acetate in parkinsonism and senility with depressive states. Study of 65 cases.
Topics: Acetates; Antidepressive Agents; Dementia; Depression; Humans; Indoles; Parkinson Disease; Parkinsonian Disorders; Psychotic Disorders | 1962 |
[Therapeutic experiences with Lucidril in neuropsychiatric disease pictures].
Topics: Acetates; Central Nervous System Stimulants; Humans; Intellectual Disability; Mental Disorders; Neurocognitive Disorders; Parkinson Disease; Psychotic Disorders | 1963 |
Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions.
Topics: Acetates; Aged; Aged, 80 and over; alpha-Synuclein; Animals; beta-Synuclein; Blotting, Western; Brain; Cell Aggregation; Cell Count; Chlorocebus aethiops; COS Cells; Female; Gene Expression Regulation; Glyceraldehyde-3-Phosphate Dehydrogenases; Green Fluorescent Proteins; Humans; Immunohistochemistry; Immunoprecipitation; Inclusion Bodies; Indoles; Lewy Bodies; Male; Microscopy, Electron, Transmission; Middle Aged; Mutagenesis, Site-Directed; Nerve Tissue Proteins; Parkinson Disease; Polymerase Chain Reaction; Synucleins; Thiazoles; Transfection; Ubiquitin | 2005 |
Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
Topics: Acetates; Animals; Brain; Brain Ischemia; Caspases; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dopamine; Genes, Reporter; Humans; Ligands; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Phenols; Phenoxyacetates; PPAR delta; Rats; Rats, Wistar; Substrate Specificity; Thiazoles | 2007 |
Effect of L-DOPA on endogenous histamine metabolism.
Topics: Acetates; Adult; Aged; Animals; Carbidopa; Depression, Chemical; Female; Guinea Pigs; Histamine; Humans; Imidazoles; Levodopa; Male; Methylation; Middle Aged; Parkinson Disease; Rats; Species Specificity | 1975 |
The determination of 4-hydroxy-3-methoxyphenylethylene glycol in urine and CSF using gas chromatography.
Topics: Acetates; Adult; Catechols; Chromatography, Gas; Chromatography, Ion Exchange; Dihydroxyphenylalanine; Female; Fluoroacetates; Glucuronidase; Glycols; Humans; Huntington Disease; Male; Mass Spectrometry; Methods; Parkinson Disease; Snails; Sulfatases | 1972 |